Search results
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
14 gru 2017 · ASP8273 demonstrated antitumor activity in patients with EGFR-mutant lung cancers after prior treatment with EGFR TKIs. This study identified the ASP8273 RP2D to be 300 mg daily based on pharmacokinetics, pharmacodynamics, safety, and antitumor activity; the MTD was not established.
Based on the mean PLCO M2012 score among screened participants (5.0%), the model predicts 71 lung cancers over 6 years. The actual number of lung cancers detected was 62 (detection rate 4.3%) after approximately 15 months (two rounds of annual screening and 3 months nodule follow-up).
5 kwi 2023 · This study aims to develop and validate a risk prediction model—the CanPredict (lung) model—for lung cancer screening in the UK and compare the model performance against seven other risk prediction models.
Individualized Lung Cancer Risks and Screening Benefit Calculator. DCEG investigators developed models to estimate a current or former smoker’s risk of developing lung cancer and their gain in life-expectancy from lung cancer screening, freely available online at ScreenLC.com. These models included:
The Breast Cancer Risk Assessment Tool (BCRAT), also known as The Gail Model, allows health professionals to estimate a woman's risk of developing invasive breast cancer over the next five years and up to age 90 (lifetime risk).
20 lip 2021 · The modified Gail model is now one of the most widely used breast cancer risk assessment tools, which sets risk thresholds of at least 1.67% for 5-year risk of breast cancer. Because it was initially developed for white women, the Gail model has been modified and validated for female Asian and Pacific Islander immigrants. [13]
